Status:
ACTIVE_NOT_RECRUITING
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
Lead Sponsor:
The Cleveland Clinic
Conditions:
Amyloidosis
Amyloid
Eligibility:
All Genders
Brief Summary
This study measures circulating, misfolded ATTR oligomers in asymptomatic ATTRm amyloidosis genetic carriers longitudinally over five years.
Detailed Description
Recent advances in genetic testing have allowed for pathogenic mutation identification in family members of affected individuals prior to onset of symptoms. While the presence of mutation and the corr...
Eligibility Criteria
Inclusion
- Patients with known hereditary ATTR amyloidosis genetic mutations as identified by genetic testing.
Exclusion
- Patients with ATTR amyloidosis identified as wild-type.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03431896
Start Date
February 1 2018
End Date
December 31 2026
Last Update
April 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic
Cleveland, Ohio, United States, 44195